Table 7.
Coverage | Reference | Citations | Author | Year | Type | Journal | IF | JCR |
---|---|---|---|---|---|---|---|---|
4 | B7-H3-targeted CAR-T cells exhibit potent antitumor effects on hematologic and solid tumors | 18 | Zhang Zongliang | 2020 | Article | Molecular Therapy: Oncolytics | 7.200 | Q4 |
4 | Targeting B7-H3 immune checkpoint with chimeric antigen receptor-engineered natural killer cells exhibits potent cytotoxicity against non-small cell lung cancer | 10 | Yang Shuo | 2020 | Article | Frontiers in Pharmacology | 5.810 | Q1 |
4 | Route of 41BB/41BBL costimulation determines effector function of B7-H3-CAR.CD28z T cells | 8 | Nguyen Phuong | 2020 | Article | Molecular Therapy: Oncolytics | 7.200 | Q4 |
4 | MEK inhibitor augments antitumor activity of B7-H3-redirected bispecific antibody | 5 | Li Hongjian | 2020 | Article | Frontiers in Oncology | 6.244 | Q2 |
4 | Chimeric antigen receptor T-cell therapy in glioblastoma: current and future | 3 | Li Long | 2020 | Review | Frontiers in Immunology | 7.561 | Q2 |
IF, impact factors; JCR, journal citation reports.